BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - May 29, 2014) - Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014, at 8:00 a.m. ET.
A live audio webcast of the presentation will be available at:
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa®(icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA and is available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
- Health Care Industry
- Investment & Company Information
Investor Relations and Corporate Communications
In U.S.: +1 (908) 719-1315